EGFR and non-small cell lung carcinoma: Activating mutations in the tyrosine kinase domain of the EGFR gene in tumour tissue predict clinical response of advanced non-small-cell lung cancer (NSCLC) to tyrosine kinase inhibitors (TKI’s) such as gefitinib and erlotinib[1-4].